Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Lilly raises outlook for third time this year as Zepbound sales soar

The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.

Lilly raises outlook for third time this year as Zepbound sales soar

We haven't written up this one. MarketWatch Top has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at marketwatch.com →

More in Finance & Markets

Textron Raises 2026 Earnings Guidance

(RTTNews) - Textron (TXT) raised its expectation for full-year 2026 GAAP earnings per share from continuing operations to be in the range of $5.64 to $5.74, up from previous outlook of $5.39 to $5.59.

Rupee extends gain against US dollar

The Pakistani rupee continued its marginal gain against the US dollar in the inter-bank market on Thursday. The local unit closed the day at 276.76, a gain of Re0.01 against the greenback.

More from Thursday 29 October →